Latest news with #N.J.
Yahoo
3 days ago
- Sport
- Yahoo
Watch Joo Sang Yoo score insane one-punch knockout in debut at UFC 316
Joo Sang Yoo could be the next great South Korean UFC star. If his debut was any indication, Yoo will be one to watch for years to come as he needed just 28 seconds to land a picture-perfect left hand on Jeka Saragih and that left him face-down on the canvas at UFC 316 in Newark, N.J. Advertisement Watch the beautiful knockout strike below. Yoo entered the bout as a heavy favorite and the commentary team of Joe Rogan and Daniel Cormier mentioned that the 31-year-old featherweight prospect has drawn comparisons to Conor McGregor. While he has a long way to go to match the achievements and fame of the former two-division UFC champion, Yoo's performance more than lived up to the hype. With Saragih charging at him and swinging wildly, Yoo calmly controlled the distance before unleashing a counter left to the chin that instantly robbed Saragih of his consciousness. The scary KO blow left Saragih staring blankly as he lied flat on the mat. Advertisement Yoo improved to 9-0 as a pro, with four of his wins coming by way of KO/TKO. More from
CTV News
26-05-2025
- Politics
- CTV News
President Donald Trump says Russian leader Vladimir Putin ‘has gone absolutely CRAZY!'
President Donald Trump speaks to reporters before boarding Air Force One at Morristown Municipal Airport in Morristown, N.J., Sunday, May 25, 2025. (AP Photo/Manuel Balce Ceneta) WASHINGTON — U.S. President Donald Trump made it clear he is losing patience with Vladimir Putin, leveling some of his sharpest criticism at the Russian leader as Moscow pounded Kyiv and other Ukrainian cities with drones and missiles for a third straight night. 'I've always had a very good relationship with Vladimir Putin of Russia, but something has happened to him. He has gone absolutely CRAZY!' Trump wrote in a social media post on Sunday night. Trump said Putin is 'needlessly killing a lot of people,' pointing out that 'missiles and drones are being shot into Cities in Ukraine, for no reason whatsoever.' The attack was the largest aerial assault since Russia's full-scale invasion of the country in February 2022, according to Ukrainian officials. At least 12 people were killed and dozens injured. The U.S. president warned that if Putin wants to conquer all of Ukraine, it will 'lead to the downfall of Russia!' But Trump expressed frustration with Ukrainian President Volodymyr Zelenskyy as well, saying that he is 'doing his Country no favors by talking the way he does.' 'Everything out of his mouth causes problems, I don't like it, and it better stop,' Trump wrote on social media. The president has increasingly voiced irritation at Putin and the inability to resolve the now three-year-old war, which Trump promised he would promptly end as he campaigned to return to the White House. He had long boasted of his friendly relationship with Putin and repeatedly stressed that Russia is more willing than Ukraine to reach a peace deal. But last month, Trump urged Putin to 'STOP!' assaulting Ukraine after Russia launched another deadly barrage of attacks on Kyiv, and he has repeatedly expressed his frustration that the war in Ukraine is continuing. 'I'm not happy with what Putin's doing. He's killing a lot of people. And I don't know what the hell happened to Putin,' Trump told reporters earlier Sunday as he departed northern New Jersey, where he spent most of the weekend. 'I've known him a long time, always gotten along with him, but he's sending rockets into cities and killing people and I don't like it at all. ' A peace agreement between Russia and Ukraine remains elusive. Trump and Putin spoke on the phone this past week, and Trump announced after the call that Russia and Ukraine will 'immediately' begin ceasefire talks. That conversation occurred after Russian and Ukrainian officials met in Turkey for the first face-to-face talks since 2022. But on Thursday, the Kremlin said no direct talks were scheduled. Seung Min Kim, The Associated Press
Associated Press
13-05-2025
- Business
- Associated Press
Cellectar Biosciences Reports First Quarter 2025 Financial Results and Provides a Corporate Update
Company Seeking Conditional Approval from European Medicines Agency (EMA) for Iopofosine I 131 in Waldenstrom Macroglobulinemia based upon CLOVER WaM Phase 2 Study Data CLOVER WaM Major Response Rate for BTKi-Treated Patients 59.0% Company to hold webcast and conference call at 8:30 AM ET today FLORHAM PARK, N.J., May 13, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced financial results for the quarter ended March 31, 2025, and provided a corporate update on its promising portfolio of clinical and pre-clinical radiopharmaceutical therapeutics. 'Notwithstanding the need to gather additional clinical data for iopofosine I 131, as previously announced, we believe that the Phase 2 CLOVER WaM clinical trial data for this product candidate are impressive. We plan to present these data to the EMA during the second quarter of 2025 as part of the registration package seeking conditional marketing approval. We anticipate a response regarding the regulatory pathway from the European agency before the end of the third quarter of this year,' said James Caruso, president and CEO of Cellectar. 'In addition to iopofosine I 131, we have developed a pipeline of radiotherapeutic candidates, including our alpha- and Auger-emitting radioconjugates, with observed preclinical activity in solid tumor models. With cash into the fourth quarter of this year we are evaluating a variety of funding pathways to successfully advance our novel pipeline assets.' Corporate Update First Quarter 2025 Financial Highlights Conference Call & Webcast Details Cellectar management will host a conference call and webcast today, May 13, 2025, at 8:30 AM Eastern Time to discuss these results and answer questions. Stockholders and other interested parties may participate in the conference call by dialing 1-800-717-1738. A live webcast of the conference call can be accessed in the 'Events & Presentations' section of Cellectar's website at A recording of the webcast will be available and archived on the company's website for approximately 90 days. About Cellectar Biosciences, Inc. Cellectar Biosciences is a late-stage clinical biopharmaceutical company focused on the discovery and development of proprietary drugs for the treatment of cancer, independently and through research and development collaborations. The company's core objective is to leverage its proprietary Phospholipid Drug Conjugate™ (PDC) delivery platform to develop the next-generation of cancer cell-targeting treatments, delivering improved efficacy and better safety as a result of fewer off-target effects. The company's product pipeline includes its lead assets: iopofosine I 131, a PDC designed to provide targeted delivery of iodine-131 (radioisotope); CLR 121225, an actinium-225 based program being targeted to several solid tumors with significant unmet need, such as pancreatic cancer; and CLR 121125, an iodine-125 Auger-emitting program targeted in other solid tumors, such as triple negative breast, lung and colorectal, as well as proprietary preclinical PDC chemotherapeutic programs and multiple partnered PDC assets. In addition, iopofosine I 131 has been studied in Phase 2b trials for relapsed or refractory multiple myeloma (MM) and central nervous system (CNS) lymphoma, and the CLOVER-2 Phase 1b study, targeting pediatric patients with high-grade gliomas, for which Cellectar is eligible to receive a Pediatric Review Voucher from the FDA upon approval. The FDA has also granted iopofosine I 131 six Orphan Drug, four Rare Pediatric Drug and two Fast Track Designations for various cancer indications. For more information, please visit or join the conversation by liking and following us on the company's social media channels: X, LinkedIn, and Facebook. Forward Looking Statements Disclaimer This news release contains forward-looking statements. You can identify these statements by our use of words such as 'may,' 'expect,' 'believe,' 'anticipate,' 'intend,' 'could,' 'estimate,' 'continue,' 'plans,' or their negatives or cognates. These statements are only estimates and predictions and are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties related to the ability to execute strategic alternatives, identify suitable collaborators, partners, licensees or purchasers for our product candidates and, if we are able to do so, to enter into binding agreements with regard to any of the foregoing, or to raise additional capital to support our operations, or our ability to fund our operations if we are unsuccessful with any of the foregoing. A complete description of risks and uncertainties related to our business is contained in our periodic reports filed with the Securities and Exchange Commission including our Form 10-K for the year ended December 31, 2024, and our Form 10-Q for the quarterly period ending March 31, 2025. These forward-looking statements are made only as of the date hereof, and we disclaim any obligation to update any such forward-looking statements. INVESTORS: Anne Marie Fields Precision AQ 212-362-1200 [email protected] +++ TABLES TO FOLLOW +++
CTV News
09-05-2025
- General
- CTV News
Oyster season opens in P.E.I. for first time since detection of MSX parasite
Shown are oysters harvested in Canada at Bryan Szeliga's Fishtown Seafood in Haddonfield, N.J., Thursday, March 6, 2025. THE CANADIAN PRESS/AP-Matt Rourke
